A Phase 3 interventional study of MC0518 and BAT in Steroid-refractory Acute Graft-versus-host Disease, sponsored by medac GmbH. Recruiting at 42 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-13.
Sponsored by medac GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Graft vs Host Disease with a site in Germany — 3 open to participants now, 9 under way, 4 of them phase 3. Graft vs Host Disease · Germany.
Among the 53 studies in Graft vs Host Disease with a site in Germany, this one is the 11th largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2021, is one of 17 in phase 3, and was the 43rd registered.
804 studies on the registry are indexed under Graft vs Host Disease; 148 are open to participants now.
Browse Graft vs Host Disease studies →3 of the 53 studies in Graft vs Host Disease with a site in Germany are open now. Recruiting first, the newest first:
Bambino Gesù Hospital and Research Institute · Sites in Germany, Austria, Czechia and 6 more countries
Ages 3 mo–25 yrs
Syndax Pharmaceuticals · Sites in Germany, United States, Australia and 13 more countries
Ages 2+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 102 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 41 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 20 · Phase 3 22 · Phase 4 2
First in 2002; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 210 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 69 across the 44 interventional studies, 50 across the 8 observational. Of the 39 that completed or were terminated, 17 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 53 have an industry lead sponsor. The 10 most frequent:
medac GmbH is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
medac GmbH has 2 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Graft vs Host Disease with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04629833Phase 3medac GmbHTreatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Graft vs Host Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this trial is to demonstrate the superiority of MC0518 compared to the first used best available therapy (BAT) with respect to overall response rate (ORR) at Day 28 and/or overall survival (OS) until Visit Month 24 in adult and adolescent subjects with steroid-refractory acute graft-versus-host disease (SR-aGvHD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.
Biological: MC0518
Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX).
Biological: BAT
MC0518 will be intravenously infused immediately after thawing.
BAT including MMF, ECP, ATG, everolimus, and RUX will be administered based on Investigator's decision.
Overall Response (OR)
OR is defined as complete response (CR) or partial response (PR) at Day 28 relative to aGvHD status at baseline. CR is defined as resolution of aGvHD in all involved organs. PR is defined as improvement in 1 stage in 1 or more organs involved with aGvHD symptoms without progression in others. Number of participants with OR will be reported.
Time frame: Day 28
Overall Survival
Overall survival is defined as the time from randomization to the date of death due to any cause.
Time frame: Up to Month 24
Freedom from Treatment Failure (FFTF)
FFTF is defined as death, relapse or progression of the underlying disease, or addition or change to any further systemic immunosuppressive aGvHD therapy. Number of participants with FFTF will be reported.
Time frame: Up to 6 months
Acute Graft-versus-host Disease (aGvHD) Response
Number of participants with aGvHD response will be reported. aGvHD response will be categorized as OR (CR + PR), CR, PR, and NR. NR is defined as the absence of CR or PR.
Time frame: Days 28, 60, 100 and 180
Change from Baseline in aGvHD Grades
aGvHD grades: Grade 0- no organ involvement (ie, Stage 0 skin, Stage 0 liver, and Stage 0 GI); Grade I-Stage 1 - 2 skin without liver/GI involvement; Grade II- Stage 3 skin and / or Stage 1 liver and / or Stage 1 GI; Grade III- Stage 2 - 3 liver and / or Stage 2 - 3 GI; Grade IV- Stage 4 skin and / or Stage 4 liver and/or Stage 4 GI.
Time frame: Baseline and Days 8, 15, 22, 28, 60, 100 and 180
Time to Response
Time to response is defined as the time from the date of the first treatment administration to the date of response.
Time frame: Up to Month 24
Duration of Response
Duration is calculated from time from the first OR (CR or PR) until the time point of no aGvHD response in comparison to baseline.
Time frame: Up to Month 24
Best Overall Response (OR)
Best OR is defined as the achievement of an OR at any time point up to and including Day 28. Number of participants with best OR will be reported.
Time frame: Up to Day 28
Cumulative Dose of Steroids for SR-aGvHD per Kilogram (kg) of Body Weight
The cumulative dose of steroids given for SR-aGvHD per kg of body weight from baseline until Day 60 and until Visit Month 24 will be analyzed.
Time frame: Up to Day 60 and Month 24
Number of Participants with Chronic Graft-versus-host Disease (cGvHD)
Number of participants with cGvHD will be reported.
Time frame: Day 60 to Month 24
Time to Chronic Graft-versus-host Disease (cGvHD)
Time to cGvHD is defined as the time between the last day of haematopoietic stem cell transplantation (HSCT) to the first episode of cGvHD.
Time frame: Day 60 to Month 24
Number of Participants with Graft Failure (GF)
Number of participants with GF will be reported.
Time frame: Up to Month 24
Number of Participants with Relapse or Progression in Participants with Underlying Malignant Disease
Number of participants with relapse or progression in participants with underlying malignant disease will be reported.
Time frame: Up to Month 24
Time to Relapse or Progression in Participants with Underlying Malignant Disease
Time to relapse or progression in participants with underlying malignant disease will be reported.
Time frame: Up to Month 24
Event-free survival (EFS)
EFS is defined as the time from the date of randomization to the date of the event. An event is defined as GF, relapse or progression of the underlying disease, or death due to any cause.
Time frame: Up to Month 24
Non-relapse Mortality (NRM)
NRM is defined as the time from the date of randomisation to the date of the event. An event is defined as death without previous relapse or progression of the underlying disease.
Time frame: Up to Month 24
Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs)
Time frame: Until Day 60 or until 30 days after last administration of trial treatment, whichever is later (Up to Month 24)
Number of Participants with Adverse Events (AEs) and Adverse Reactions (ARs) by Severity
Severity will be graded based on Common Terminology Criteria for Adverse Events (CTCAE) v5.0: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 4- Death related to the AE.
Time frame: Until Day 60 or until 30 days after last administration of trial treatment, whichever is later (Up to Month 24)
Change from Baseline in Performance score based on Karnofsky scale (recipient age >= 16 years)
The Karnofsky performance score (KPS), which is reported on an ordinal scale from 0 to 100, provides a rough measure of the participant's well-being, including their ability to conduct activities of daily living and functional capacity. Higher score indicates normal, no complaints and no evidence of disease.
Time frame: Baseline, Days 8, 15, 22, 28, 60 and 100
Change from Baseline in Performance score based on Lansky Scale
A Lansky score (recipient age greater than or equal to \[\>=\] 1 years and less than \[\<\] 16 years) will be recorded pre-treatment and measured serially at regular intervals after treatment. The score is a standard performance score that measures overall function of the child with a scale range from 0 to 100. Higher score indicates full activeness.
Time frame: Baseline, Days 8, 15, 22, 28, 60 and 100
Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Health Status Index (HSI)
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "TODAY". Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health).
Time frame: Baseline, Days 28, 60, 100 and 180
Change from Baseline in EuroQol-5D-5L (EQ-5D-5L): Visual Analogue Scale (VAS)
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine).
Time frame: Baseline, Days 28, 60, 100 and 180
Change from Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Score
The FACT-BMT questionnaire was designed to measure the quality of life in subjects undergoing bone marrow (BM) transplantation. It consists of the following categories of assessment: physical well-being, social / family well-being, emotional well-being, functional well-being, and additional miscellaneous concerns that the subject may have concerning their healthcare, persons involved in their life, and other emotions and incapabilities. Score ranges from 0-164, with higher score indicating better quality of life.
Time frame: Baseline, Days 28, 60, 100 and 180
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2021 (actual). Primary completion is estimated for Aug 2027, 72 months after the start.
Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's planned 72 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.